Published: 20 October 2026
Medically reviewed by Dr. Pranay Shah, MS (ObGy), Director & Chief Fertility Consultant, Wellspring IVF & Women’s Hospital, Ahmedabad
Last medically reviewed: 20 October 2026
A report showing no sperm in the ejaculate is not a final answer, and it is not a diagnosis on its own. The next steps are fixed and they follow a sequence: the finding is confirmed on a second, centrifuged sample; a physical examination and hormone tests establish whether sperm production or sperm transport is the problem; and genetic testing is completed before any surgical plan is made. Each result narrows the plan.
Most men receive this report by email or over a counter, without explanation, and the hours that follow are among the most distressing in a couple’s fertility journey. This article sets out what actually happens next, in what order, and what each result changes — so that the next appointment is a conversation about a plan rather than a re-reading of the same report.
What does azoospermia actually mean?
Azoospermia means that no spermatozoa are found in the ejaculate. The definition matters more than it looks. Under the AUA/ASRM guideline on the diagnosis and treatment of infertility in men, azoospermia is “the absence of sperm in the ejaculate, including the absence of sperm after examination of a centrifuged semen pellet.” A report that simply says “nil sperm seen” without stating that the sample was spun down and the pellet examined has not yet met that definition.
This is not a technicality. If a small number of sperm are present but too few to be seen on a routine slide, that changes everything: those sperm can be used for fertilisation, and no operation is needed to find them. The condition is common enough to be worth excluding deliberately.
Step 1 — The diagnosis has to be confirmed on a second sample
No treatment decision should be made on a single semen analysis. The European Association of Urology guidelines on male infertility make a strong recommendation to “perform at least two consecutive semen analyses if the baseline analysis was abnormal.” The AUA/ASRM guideline adds a practical detail: “at least two SAs, ideally obtained at least one month apart, are important to obtain.”
The second sample must also be processed correctly. The EAU guidance specifies the method for distinguishing true azoospermia from cryptozoospermia — a very small number of sperm present — as “semen centrifugation at 3,000g for 15 minutes and a thorough microscopic examination by phase contrast optics at ×200 magnification of the pellet.” The stated purpose is “to ensure that small quantities of sperm are detected, which may be potentially used for intra-cytoplasmic sperm injection (ICSI); therefore, removing the need for surgical intervention.”
In plain terms: a properly processed repeat sample can spare some men an operation altogether. If your report does not state that the sample was centrifuged, ask for that specifically when the repeat test is arranged.
Two other collection factors are worth checking before assuming the result is real: whether the full sample was collected (a spilled first fraction can lose most of the sperm), and whether the man had a high fever, a significant illness or a course of medication in the preceding weeks.
Step 2 — What the examination and the report already reveal
Before any expensive test, two pieces of information are usually already available and they carry considerable weight.
Semen volume and pH. A low-volume, acidic sample points towards a problem with the seminal vesicles or the vas deferens rather than with sperm production. The EAU guidance is explicit: “All males with azoospermia should be carefully examined to exclude CBAVD, particularly those semen volume < 1.0 mL and acidic pH < 7.0.” CBAVD is congenital bilateral absence of the vas deferens — the tubes that carry sperm are simply not there. Sperm production in these men is usually entirely normal.
Physical examination. Testicular volume and whether both vasa deferentia can be felt are assessed by hand, and by scrotal ultrasound where needed. The EAU guidance advises assessing testicular volume “with a Prader’s orchidometer or testicular ultrasound,” noting that mean volume in the European general population is 20.0 ± 5.0 mL against 18.0 ± 5.0 mL in infertile men. Small, soft testes alongside absent vasa deferentia tell two entirely different stories.
If the ejaculate volume is very low or absent, the semen may be travelling backwards into the bladder instead of forwards. The ASRM committee opinion on diagnostic evaluation of sexual dysfunction in the male partner describes the test for this: “When there is no ejaculation, then the postejaculatory urine can be analyzed to assess retrograde ejaculation,” and confirms that “sperm can be collected from men with retrograde ejaculation using postejaculatory urine specimens and used for either IUI or IVF.” This is a urine test, not an operation, and it is easily missed.
Step 3 — Hormone testing
Blood tests for follicle-stimulating hormone (FSH), luteinising hormone (LH) and total testosterone are standard at this point. The EAU guidance recommends performing “a hormonal evaluation including serum total testosterone and follicle stimulating hormone/luteinising hormone in all cases of oligozoospermia and azoospermia,” and the AUA/ASRM guideline recommends hormonal evaluation for men with “oligozoospermia or azoospermia, atrophic testes.”
The pattern is more informative than any single value. A raised FSH with small testes suggests that the testis is not producing sperm and the pituitary is working harder to compensate. A normal FSH with normal testicular volume is more consistent with a blockage. A low FSH and low LH together with low testosterone points towards a pituitary or hypothalamic cause — which is the one group in whom medical treatment, rather than surgery, may restore sperm production.
One important caution: FSH is a guide to the category, not a verdict on whether sperm can be found. The EAU guidance states plainly that “FSH levels do not accurately predict the presence of spermatogenesis.” A man should not be told that surgery is pointless on the basis of an FSH value alone.
Step 4 — Genetic testing, before any surgery is planned
Genetic testing in azoospermia is not a formality and it is not something to be arranged afterwards. It changes whether an operation should be offered at all, and it changes what the couple needs to know about any child conceived.
The AUA/ASRM guideline recommends that “karyotype and Y-chromosome microdeletion analysis should be recommended for men with primary infertility and azoospermia or severe oligozoospermia (<5 million sperm/mL) with elevated FSH or testicular atrophy.” The EAU guidance makes a strong recommendation to “offer standard karyotype analysis and genetic counselling to all men with azoospermia.”
Test | What it looks for | What the result can change |
|---|---|---|
Karyotype | Chromosomal abnormalities, most commonly Klinefelter syndrome (47,XXY) | Klinefelter syndrome does not rule out biological fatherhood. The EAU guidance notes that with TESE or micro-TESE, “spermatozoa can be recovered in up to 50% of cases.” It does change the genetic counselling the couple should receive. |
Y-chromosome microdeletion (AZFa, AZFb, AZFc) | Missing segments of the Y chromosome that carry genes needed for sperm production | The single most consequential result in the whole workup. See below. |
CFTR gene testing (man and partner) | Cystic fibrosis gene mutations, including the 5T allele | Recommended by AUA/ASRM “in men with vasal agenesis or idiopathic obstructive azoospermia.” If the female partner is also a carrier, the couple must be counselled before proceeding. |
Why the Y-microdeletion result matters most. The AUA/ASRM guideline states that “sperm may be found in the ejaculate of some men and through testicular sperm extraction in at least 50% of men with an AZFc deletion, sperm have not been retrieved by testicular sperm extraction in men with complete AZFa and/or AZFb microdeletions, so surgical intervention is not indicated.” The EAU guidance issues this as a strong recommendation: “Do not perform testicular sperm extraction in patients with complete deletions that include the AZFa and AZFb regions,” and separately notes that “testicular sperm can be found in 50–75% of males with AZFc microdeletions.”
A single blood test therefore separates men who should be offered surgical retrieval from men for whom an operation would carry risk and cost with essentially no prospect of success. Any plan that schedules a retrieval procedure before this result is available should be questioned.
The EAU guidance also makes a counselling point that is easy to overlook: “Inform males with Yq microdeletion and their partners who wish to proceed with ICSI that microdeletions will be passed to sons.” That is a conversation to have before treatment, not afterwards.
The two categories, and why the distinction is the whole plan
Everything above is directed at one question: is this a production problem or a transport problem? Obstructive azoospermia means sperm are being made but cannot get out. Non-obstructive azoospermia means production itself is impaired or absent. The category determines which retrieval technique is appropriate, how likely it is to succeed, and whether medical treatment has any role. The full side-by-side comparison, including the retrieval approach used for each and the outcomes associated with them, is set out on our azoospermia page.
Are there causes that resolve without surgery?
Sometimes, and this is worth establishing early because the answer changes the plan completely.
Hypogonadotropic hypogonadism. Where the pituitary is not sending the signal, the testis may be capable of working once the signal is restored. The AUA/ASRM guideline part II states that “spermatogenesis can be initiated and pregnancies achieved in many men with idiopathic HH when they are treated with exogenous gonadotropins or pulsatile GnRH.” This is medical treatment over months, not a quick fix, but it is a genuine route to sperm in the ejaculate.
Exogenous testosterone and anabolic steroids. This is the most commonly missed reversible cause, and men often do not volunteer it. The AUA/ASRM guidance explains the mechanism directly: “exogenous testosterone administration provides negative feedback… that can result in inhibition of gonadotropin secretion… spermatogenesis may decrease or cease altogether, resulting in azoospermia.” The EAU guidance lists anabolic drugs among gonadotoxic exposures to be excluded on history. Testosterone prescribed for low testosterone, testosterone bought privately, and gym-supplied anabolic steroids all act the same way. Recovery after stopping is possible but is not guaranteed and is not quick, which is precisely why it must be identified before anything else is planned.
Retrograde ejaculation. Covered above — a urine test, not an operation.
Recent illness, fever, chemotherapy or radiotherapy, and certain medications. These belong in the history at the first consultation. Some are reversible; some are not; all of them change how the repeat semen analysis should be interpreted.
What does not reliably reverse azoospermia is a course of over-the-counter antioxidants, a diet plan, or an unexplained “sperm booster” preparation. Where a specific, identified cause exists, treating that cause is reasonable. Empirical supplementation in a man with no sperm at all is not a treatment plan.
Where the pathway leads
What the evaluation finds | What this usually indicates | What typically follows |
|---|---|---|
Sperm found on the repeat centrifuged sample | Cryptozoospermia rather than true azoospermia | No surgical retrieval needed; sperm from the ejaculate can be used for ICSI |
Normal FSH, normal testicular volume, absent or blocked vasa | Obstructive pattern | Sperm retrieval from the epididymis or testis, with CFTR testing for both partners where the vasa are absent |
Raised FSH, reduced testicular volume, no obstruction | Non-obstructive pattern | Genetic testing first; microsurgical retrieval considered depending on the result |
Complete AZFa and/or AZFb deletion | Sperm production absent in the relevant compartment | Surgical retrieval is not indicated; the discussion moves to donor sperm or adoption, with genetic counselling |
AZFc deletion | Production impaired but often present | Retrieval is reasonable; counselling that sons will inherit the deletion |
Low FSH, low LH, low testosterone | Hypogonadotropic hypogonadism | Medical therapy with gonadotropins before considering surgery |
Testosterone or anabolic steroid use identified | Suppressed spermatogenesis | Stop the agent; re-evaluate after an interval before any surgical decision |
Where sperm are retrieved surgically, they are used with intracytoplasmic sperm injection rather than conventional IVF, because retrieved sperm are too few and too immature for fertilisation to occur unassisted. The retrieval techniques themselves — TESA and PESA, and microsurgical extraction — are described in detail on their own page, including how the procedure is timed against the female partner’s cycle and how surplus sperm are frozen for later use.
Your partner’s evaluation should begin now, not afterwards
This is the step most often deferred, and deferring it costs months. The AUA/ASRM guideline is unambiguous: “for initial infertility evaluation, both male and female partners should undergo concurrent assessment,” because “couple infertility may be due to male factors, female factors or a combination of male and female factors therefore parallel evaluation of both partners is always required.”
There is a practical reason as well as a principled one. If sperm are retrieved, the treatment that follows is an IVF cycle in the female partner. Her ovarian reserve, uterine cavity and tubal status all shape what that cycle will look like and how likely it is to succeed. Discovering an unaddressed female factor after a retrieval procedure has already been performed is avoidable.
A realistic timeline
Period | What usually happens |
|---|---|
Week 1 | Consultation, full history including medication and supplement use, physical examination, repeat semen analysis arranged with explicit instructions for centrifugation |
Weeks 2–6 | Repeat centrifuged semen analysis (at least a month after the first); hormone profile; scrotal ultrasound where indicated; post-ejaculatory urinalysis if the volume is low |
Weeks 4–8 | Karyotype and Y-chromosome microdeletion results; CFTR testing for both partners where indicated; female partner’s evaluation running in parallel |
Weeks 8–10 | Results consultation. The category is now established and a specific plan — medical therapy, surgical retrieval, or donor and adoption counselling — is agreed |
Genetic test turnaround varies between laboratories and is often the rate-limiting step. Asking when the sample will be dispatched and when the report is expected is a reasonable question to put at the time the test is ordered.
Questions worth asking at the next appointment
- Was the second sample centrifuged and the pellet examined, and does the report say so?
- What are my FSH, LH and total testosterone values, and what is my testicular volume?
- Have the karyotype and Y-chromosome microdeletion tests been sent, and when will the results be available?
- Am I taking, or have I taken, anything that could be suppressing sperm production?
- Are we treating this as obstructive or non-obstructive, and what is that judgement based on?
- Has my partner’s evaluation started, and what does it involve?
- If sperm are retrieved, will surplus sperm be frozen at the same time?
When specialist evaluation is appropriate
A single semen analysis reporting no sperm is itself sufficient reason for review by a fertility specialist, and there is no benefit in waiting. Earlier review is particularly important where the female partner is over 35, where there is a history of undescended testes, testicular surgery, torsion, mumps orchitis, chemotherapy or radiotherapy, where testosterone or anabolic steroids have been used, or where a previous clinic has proposed surgical retrieval without completing genetic testing first.
Azoospermia evaluation is one of the areas where the sequence of investigation matters as much as the investigations themselves. At Wellspring IVF & Women’s Hospital, an ART-registered IVF clinic in Ahmedabad, Gujarat, this pathway is overseen by our Director & Chief Fertility Consultant, Dr. Pranay Shah, MS (ObGy), who has more than 15 years of experience in reproductive medicine.
Frequently asked questions
What tests follow an azoospermia diagnosis?
A repeat semen analysis on a centrifuged sample at least a month later; physical examination with testicular volume assessment; blood tests for FSH, LH and total testosterone; scrotal ultrasound where indicated; a post-ejaculatory urinalysis if the volume is low; and genetic testing comprising karyotype and Y-chromosome microdeletion analysis, with CFTR testing where the vas deferens is absent.
Is genetic testing needed for azoospermia?
Yes. Both AUA/ASRM and EAU guidance recommend karyotype and Y-chromosome microdeletion testing in azoospermia. The result is not academic: a complete AZFa or AZFb deletion indicates that surgical sperm retrieval is not appropriate, while an AZFc deletion carries a reasonable prospect of retrieval. Testing should be completed before a retrieval procedure is scheduled.
Can azoospermia be reversed with medication?
In a minority of men, yes. Where the cause is hypogonadotropic hypogonadism, gonadotropin or GnRH therapy can initiate sperm production. Where exogenous testosterone or anabolic steroids are responsible, stopping them may allow recovery, though this is neither guaranteed nor rapid. Where the testis itself has failed, no medication restores production, and general supplements are not a treatment.
Does a single report showing no sperm confirm the diagnosis?
No. Guidelines require at least two semen analyses when the first is abnormal, and the diagnosis is only established when no sperm are seen after the sample has been centrifuged and the pellet examined under phase contrast microscopy. A small number of sperm found on the repeat sample can remove the need for surgery entirely.
Does azoospermia affect testosterone, libido or sexual function?
Not necessarily. Many men with azoospermia have entirely normal testosterone levels and normal sexual function, particularly where the cause is obstructive. Where testosterone is low, that is identified on the hormone profile and managed as part of the overall plan, taking care that testosterone replacement itself does not further suppress any remaining sperm production.
How long does the evaluation take?
Usually eight to ten weeks from first consultation to a settled plan. The repeat semen analysis is deliberately spaced a month or more after the first, and genetic testing generally takes several weeks. The female partner’s evaluation runs alongside rather than afterwards, so no time is lost.
The takeaway
A report showing no sperm is the beginning of an evaluation, not the end of a possibility. The sequence is confirmation, categorisation, then genetics — and only then a treatment decision. Men whose azoospermia proves to be obstructive, whose repeat sample reveals a few sperm, whose hormone profile identifies a treatable pituitary cause, or who carry an AZFc rather than an AZFa or AZFb deletion all have realistic routes to biological fatherhood. Skipping steps, or scheduling surgery before the genetic results are back, is what closes those routes prematurely.
Couples who have received an azoospermia report and want the evaluation done in the right order can discuss their situation with a fertility specialist at Wellspring IVF & Women’s Hospital, Ahmedabad, on +91 9099946050. OPD hours are Monday to Saturday, 10:00 AM to 4:00 PM.
References
- World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen, 6th edition. Geneva: World Health Organization; 27 July 2021. ISBN 978-92-4-003078-7. https://www.who.int/publications/i/item/9789240030787
- Schlegel PN, Sigman M, Collura B, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I. Fertility and Sterility 2021;115:54–61. American Society for Reproductive Medicine. https://www.asrm.org/practice-guidance/practice-committee-documents/diagnosis-and-treatment-of-infertility-in-men-auaasrm-guideline-part-i-2020/
- Schlegel PN, Sigman M, Collura B, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part II. American Society for Reproductive Medicine; 2021. https://www.asrm.org/practice-guidance/practice-committee-documents/diagnosis-and-treatment-of-infertility-in-men-aua-asrm-guideline-part2/
- Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of sexual dysfunction in the male partner in the setting of infertility: a committee opinion (2023). https://www.asrm.org/practice-guidance/practice-committee-documents/diagnostic-evaluation-of-sexual-dysfunction-in-the-male-partner-in-the-setting-of-infertility-a-committee-opinion-2018/
- European Association of Urology. EAU Guidelines on Sexual and Reproductive Health — Male Infertility. 2025 edition. https://uroweb.org/guidelines/sexual-and-reproductive-health/chapter/male-infertility
